Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06583031
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-30
Brief Title:
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV Respiratory Syncytial Virus and hMPV Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Randomized Modified Double-blind Multi-center Parallel Group Multi-arm Study to Investigate the Safety and Immunogenicity of an RSVhMPV Vaccine Candidate in Adult Participants Aged 60 to 75 Years
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
VAV00039 is a first-in-human FiH study to assess the safety and immunogenicity in adult participants aged 60-75 years after a single injection of different dose formulations of an RSVhMPV vaccine candidate and RSV vaccine
Detailed Description:
The duration of participation will be approximately 6 months for each participant
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None